GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » 5-Year EBITDA Growth Rate

Pharmala Biotech Holdings (XCNQ:MDMA) 5-Year EBITDA Growth Rate : 0.00% (As of Feb. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings 5-Year EBITDA Growth Rate?

Pharmala Biotech Holdings's EBITDA per Share for the three months ended in Feb. 2024 was C$-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Pharmala Biotech Holdings's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Pharmala Biotech Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's 5-Year EBITDA Growth Rate falls into.



Pharmala Biotech Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Pharmala Biotech Holdings  (XCNQ:MDMA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Pharmala Biotech Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines